This fact sheet provides some useful information about rational use of medicines. Rational use of medicines refers to the correct, proper and appropriate use of medicines. Rational use requires that patients receive the appropriate medicine, in the proper dose, for an adequate period of time, and at the lowest cost to them and their community
This paper is based on a presentation given in the Philippines on the right to health. Several topics were tackled there, from drug prices and price control, to drug availability, patent for new medicines, health insurance, among others. The focus was on the philosophy of 'health as a right' juxtaposed with 'health as personal responsibility'. The paper concludes that rather than favouring one group of pharma companies and demonising another, public policy should focus on expanding the people’s options in choosing the right mixture of medicines and healthcare that are appropriate for them given their existing resources and health needs
The unique position of stakeholders participating in the Medicines Transparency Alliance Zambia, means that the group are able to initiate discussions at many levels from grassroots to parliament. This is of great value in highlighting critical issues about the lack of access to essential medicines experienced by many citizens in Zambia and makes progress towards finding some solutions
This is a synthesis which aims to provide a quick reference of suggested communication approaches for health researchers and monitoring and evaluation professionals in order to facilitate stakeholders’ use of health information for decision-making
This manual aims to provide simple, practical solutions to the questions and problems faced by medical staff involved in curative care and drug management. The list of drugs in this edition has been revised in line with the most recent World Health Organization list of essential medicines.
This fact sheet gives a brief overview of the key facts regarding corruption in the pharmaceutical supply chain. It focuses on unethical practices in the medicines supply chain, factors contributing to pharmaceutical corruption, the impact of corruption, and the response of the WHO
This article examines medicines price competition that ensued in a rural village in Kyrgyzstan after the opening of a small network of non-profit pharmacies created and managed by an NGO. While the rural pharmacies were created to increase access to medicines in villages where no pharmacies existed, the project had unexpected, substantial spillover effects, spurring medicines price reductions in pharmacies quite far away
Daniel Kaufmann and Mushtaq Khan debate the role and importance of tackling corruption as part of a development strategy. Daniel Kaufmann led the work on governance at the World Bank Institute until November 2008, and is currently a Senior Scholar at the Brookings Institution. Mushtaq Khan is Professor of Economics, Department of Economics, School of Oriental and African Studies, University of London. The session is facilitated by Owen Barder, a former UK Department for International Development (DFID) official, now working for Development Initiatives
The local manufacturing of pharmaceuticals is a hotly contested issue in many countries. It runs to the heart of key concerns such as quality, availability, and price of medicines. Some of the arguments of the local manufacturers are set out in this article by one of the co-chairs of the Medicines Transparency Alliance Uganda Council and Chairman of the Uganda Pharmaceutical Manufacturer's Association (UPMA)
This report focuses on three of 10 sub-Saharan countries that were covered by a study examining the quality of key antimalarial medicines. A total of 491 samples of anti-malarial medicines (both artemisinin-based combination therapy and sulfadoxine-pyrimethamine products) were collected from the public sector, the regulated private sector and the informal market in these three countries. The study revealed a high failure rate among sampled antimalarials in all three countries, based both on Minilab and full-compendial or quality control laboratory testing
This issue has articles about medicine prices in Vietnam, Thailand and South Africa, generic medicines in Malaysia and Australia, anti-retroviral therapy in South Africa, and legislation and regulation in the retail pharmacy sector in low-income countries.
Southern Med Review : Vol 2, Issue 2
This research report considers the challenges faced by a local pharmaceutical firm - Quality Chemicals - in Uganda, which was started up as a 'solution' to reducing the high cost of medicines and improving access to medicines. "...many burdens and barriers to access continue to seriously hinder the success of such enterprises. Indirect government subsidies to exporters selling into African markets, and pressure by donors and lobbyists on innovator producers to offer developing countries subsidised prices, actually undermine the competitiveness and viability of these nascent firms. Furthermore, the focus on drug pricing and local production can actually undermine the overall aim to increase access to medicines"
This is a practical guide on how to improve searching techniques for finding electronic information about medicine and health and thus produce better search results. Improved online search techniques save users time because refining the search leads to fewer and more targeted search results. The primary target groups include clinicians, researchers, teachers, policymakers, and community workers in the health sector, as well as librarians and information specialists in this field
This article looks at the ideas that Medicines Transparency Alliance (MeTA) is testing, in order to achieve its long term goal to make high-quality essential medicines available and affordable to poor people who are currently unable to access them; and at how these ideas are being put into practice in Ghana. Ghana is one of the seven countries involved in the pilot phase of MeTA, the other countries are Jordan, Kyrgyzstan, Peru, the Philippines, Uganda and Zambia
This article reports on a study which examined the availability of certain drugs in Guatemala and found that the Central America Free Trade Agreement (CAFTA) intellectual property rules reduced access to some generic drugs already on the market and delayed the new entry of other generics. It found that some drugs protected from competition in Guatemala will become open for generic competition in the United States before generic versions will be legally available in Guatemala
This is a practical, do-it-yourself guide for leaders and facilitators wanting to help organisations to function and to develop in more healthy, human and effective ways as they strive to make their contributions to a more humane society... The guide, with its supporting website, includes tried and tested concepts, approaches, stories and activities. Its purpose is to help stimulate and enrich the practice of anyone supporting organisations and social movements in their challenges of working, learning, growing and changing to meet the needs of our complex world. Although it is aimed at leaders and facilitators of civil society organisations, we hope it will be useful to anyone interested in fostering healthy human organisation in any sphere of life. This resource has a supporting website where additional resources are available
There are dozens of emerging interactive web services and applications, sometimes referred to as the ‘participatory’, ‘social’ or ‘readwrite’ web, but more commonly known as Web 2.0. Together, they are radically changing the ways we create, share, collaborate and publish digital information through the Internet. These new technical opportunities bring challenges as well as opportunities that we need to understand and grasp. Most of the themed articles are based on presentations made at the the international Web2forDev conference, 25-27 September 2007 at the Food and Agriculture Organization (FAO) headquarters in Rome, Italy
This paper is about substances that are sold as medicines yet are not what they purport to be. Some of these substances are deliberately mislabeled, i.e. counterfeit. Others may have been inadvertently mislabelled or the pills contaminated during manufacture. Others may originally have been exactly as they claim, but due to poor storage have degraded and are consequently substandard. The paper is composed of four parts. The first looks at the scope of the problem in less developed countries; the second examines the health impacts of fake medicines; the third section considers the main causes of the problem; and the final section offers some possible solutions
This paper argues that, between North and South, there are more common health interests in pharmaceutical policies, within broader global public policies, than are currently articulated
Irrational use of medicines is one of the most serious global public health problems we face today. Improving use requires regular monitoring and application of effective interventions, both of which are often not done, particularly in many lower income countries. To address this issue, WHO created a database of medicines use in in primary care settings in developing and transitional countries. Quantitative information has been extracted from 679 studies conducted in 97 countries and on 386 interventions (from 313 studies). The medicines use database has allowed the first systematic quantitative review of studies measuring medicines use in developing and transitional countries and the results are now presented
Source e-bulletin on Disability and Inclusion